Thythy Pham, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1285880757
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Biofire Diagnostics, LLC at 59.8% of the total. Reporting peaked in 2019 at $5,840 and has fallen 91.2% since, to $514 in 2025.
Across 43 payments — averaging $175.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofire Diagnostics, LLC$5K
- Boston Scientific$2K
- Medical Device Business Services, Inc.$325
- Axonics, Inc.$260
- Ferring Pharmaceuticals Inc.$87
- Medtronic$60
- plus $76 from 2 others
What the payments were for
- Consulting fees$4256%
- Speaking & faculty fees$2,00026%
- Travel & lodging$3,14242%
- Food & beverage$1,66722%
- Education$3254%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biofire Diagnostics, LLC | 10 | $4,517 |
| Boston Scientific | 19 | $2,235 |
| Medical Device Business Services, Inc. | 1 | $325 |
| Axonics, Inc. | 5 | $260 |
| Ferring Pharmaceuticals Inc. | 1 | $87 |
| Medtronic | 3 | $60 |
| Cook Medical LLC | 3 | $51 |
| Femselect Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioFire FilmArray$4,380
- SOLYX$1,138
- GENERAL - THERAPIES$425
- Advantage System$236
- Bulkamid$180
- Axonics$180
- GENERAL PELVIC ORGAN PROLAPSE$100
How this compares
$7,559 in reported general payments places this provider in the 70th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 43 | $43,931 |
| GemtesaVibegron | 46 | $38,968 |
| Estradiol | 107 | $6,168 |
| Methenamine Hippurate | 49 | $2,536 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Ankita GuptaChicago$7K
- Sarah AdelsteinChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.